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Abstract 
Background: Lichen planus is a common skin disorder of unknown etiology. Most cases are 
idiopathic, but substances such as gold, antimalarials, penicillamine, thiazide diuretics, β-
blockers, arsenic and nonsteroidal anti-inflammatory drugs have been implicated as trigger 
factors. Case Presentation: We report the case of a lichenoid eruption in a male drug addict 
who administered oral heroin (diamorphine) intravenously. Diamorphine was stopped 
immediately. Following topical steroids, phototherapy and oral acitretin, the lesions gradually 
disappeared. A lymphocyte transformation test was negative for pure morphine and codeine. 
Discussion: A coincidental association between the intravenous application of orally 
formulated semisynthetic heroin and the lichenoid eruption cannot be completely ruled
 
out. 
However, the diagnosis of a lichenoid drug eruption is favoured over idiopathic lichen planus 
because of the clear chronological correlation between drug use and appearance as well as 
drug withdrawal and disappearance of the skin lesions, and because of a flare-up following 
repeated intravenous application of diamorphine. 
© 2013 S. Karger AG, Basel 
Case Presentation 
We report the case of a 40-year-old male intravenous drug abuser who presented to our 
outpatient clinic with a 2-week history of pruritic skin eruption on his palms and soles. The 
patient worked part-time as a carpenter and related the appearance of the skin lesions to 
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exposure to a cleaning agent the previous day when he was working barefoot and with 
ungloved hands. On clinical examination, he presented with multiple, erythematous, flat-
topped, lightly scaly, pruritic papules on his palms and soles, with a predilection for the 
wrists (fig. 1). Painless, white, nonremovable streaks (leukokeratosis) were also seen on the 
mucosa of the cheeks. A rash consisting of small polygonal papules affecting the rest of the 
body’s surface was additionally observed (fig. 2). 
The patient had been an intravenous heroin abuser for many years and had enrolled in 
an outpatient opiate-based support program. In this context, he was dispensed oral 
semisynthetic diamorphine (Diaphin®) under supervision. On repeated questioning, he 
revealed that he had administered the provided synthetic oral heroin intravenously for the 
last 6 months on a regular basis. He used to dissolve the tablets in water and heat the 
mixture before injecting it intravenously. He stated that he was additionally using ‘street’ 
heroin from time to time. Apart from diamorphine and street heroin, he was not taking any 
other illegal drugs or medication. 
Our clinical differential diagnosis included a contact allergy to a cleaning agent, a sudden 
aggravation of an underlying atopic dermatitis, palmoplantar psoriasis, and lichen planus. 
The histopathologic examination of the samples taken from the right sole showed hyperker-
atosis and irregular acanthosis with a band-like dermal infiltrate at the dermo-epidermal 
junction with eosinophilic colloid bodies and melanophages, consistent with a diagnosis of 
lichen planus (fig. 3). A biopsy taken from the patient’s back also revealed lichenoid changes 
showing focal interface dermatitis with lymphocytes at the dermo-epidermal junction and 
slight vacuolization of keratinocytes (fig. 4). 
Extensive blood workup, including screening for HIV, HBV, HCV and syphilis, was within 
normal limits except for slightly elevated liver transaminases. Total IgE was moderately 
elevated at 565 kU/l. Urine drug screening was negative except for methadone and opioids. 
A contact allergy to disinfectants, metals and resins was excluded by patch testing. Be-
cause of the possible relationship of lichen planus with drugs, Diaphin was discontinued and 
replaced by orally formulated methadone and morphine. A lymphocyte transformation test 
to measure drug-specific T cells was performed. Oral Diaphin was not available for testing. 
The lymphocyte transformation test was thus performed using pure morphine and codeine 
and was negative. An allergic reaction to Diaphin could not be excluded or confirmed by 
testing. Nevertheless, in a self-experiment the patient once again administered the oral 
formulation of diamorphine intravenously and noticed immediate worsening of the skin 
lesions and swelling of the hands. 
The patient was treated with topical steroids, phototherapy with narrowband UVB (311 
nm) and oral antihistamines. Because of the intense skin involvement, systemic therapy with 
acitretin (Neotigason®) was initiated. Due to side effects (headache and nausea), the initial 
daily acitretin dose of 25 mg was reduced to 10 mg per day. All treatments (acitretin, 
phototherapy and topical steroids) were discontinued by the patient after 2–3 months and 
replaced by emollients only. The lichenoid skin changes on his body, palms and soles 
completely resolved within the following 6 months. 
Discussion 
Diamorphine (diacetylmorphine) is a semisynthetic opioid drug synthesized from mor-
phine. Diamorphine tablets seem to be an effective and safe mode of application of 
diamorphine in the context of heroin substitution [1]. In Switzerland, diamorphine is 
dispensed to a highly selected, registered group of severely addicted, long-term intravenous 
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opioid abusers. Diamorphine frequently causes hypersensitivity reactions like urticarial 
reactions (hives) or itching due to histamine liberation. 
Lichen planus is a common skin disorder of unknown etiology. Most cases of lichen 
planus are idiopathic, but a wide range of substances such as gold, antimalarials, penicilla-
mine, thiazide diuretics, β-blockers, arsenic and nonsteroidal anti-inflammatory drugs have 
been implicated as triggering agents [2]. A latency period of several months from introduc-
tion of the causative drug to presentation of lichenoid skin lesions usually occurs. The time 
course from drug cessation to resolution of the skin lesions ranges from several weeks to 
months. 
Differentiating drug-induced lichen planus from the idiopathic form is difficult. In idio-
pathic lichen planus, flat-topped, shiny, violaceous papules with Wickham’s striae and a 
predilection for the wrists, flexures, genitalia and mucous membranes are seen. It has been 
described that drug-induced lichen planus may appear psoriasiform or eczematous, rarely 
involves the mucosae and affects older patients and photoexposed areas [1, 3]. Histopatho-
logic findings including the presence of plasma cells, neutrophils and eosinophils in the 
cellular infiltrate, focal eosinophils with a thin epidermis and hypogranulosis, and a 
superficial and deep perivascular infiltrate are features associated more commonly with 
drug-induced lichen planus [1, 4]. 
We lack specific allergy tests supporting our clinical diagnosis of a lichenoid drug erup-
tion in our patient. A coincidental association between the intake of the semi-synthetic 
heroin and the lichenoid eruption cannot be completely ruled out. However, the diagnosis of 
a lichenoid drug eruption is favoured over idiopathic lichen planus because of the closely 
linked onset of the disease and the complete resolution after withdrawal of drug as well as 
the flare-up after repeated intravenous application of oral diamorphine. The presence of 
eosinophils and neutrophils in the dermal perivascular infiltrate in the histopathologic 
specimens is another finding in favour of a lichenoid drug eruption. 
Potential eliciting agents comprise diamorphine itself, another component of the prepa-
ration, contaminating agents of the self-made intravenous formulation or possibly another 
illicit drug intake [5, 6]. As the repeated intravenous application of oral diamorphine caused 
a flare-up of the lichenoid eruption, we conclude that this particular oral formulation of 
diamorphine is most likely to have caused the lichenoid drug eruption in our patient 
following intravenous application. In conclusion, drugs should be strictly applied as 
formulated, and routes of administration should not be interchanged. 
Disclosure Statement 
None. 
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Fig. 1. Swollen palms and soles with thick, infiltrated hyperkeratotic plaques; at the borders red-
violaceous, well-circumscribed papules are covered with superficial fine white lines. 
 
 
 
Fig. 2. Multiple, small, erythematous, flat-topped papules cover the entire surface of the body, sparing the 
head. 
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Fig. 3. A biopsy taken from the right sole shows acanthosis, hyperkeratosis, hypergranulosis and a band-
like lymphocytic infiltrate at the dermo-epidermal junction with eosinophilic colloid bodies and 
melanophages, consistent with a diagnosis of lichen planus. 
 
 
 
Fig. 4. A biopsy taken from the patient’s back shows focal interface dermatitis with lymphocytes at the 
dermo-epidermal junction and vacuolization of keratinocytes. 
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